Johnson & Johnson's Ethicon Ordered to Pay $76.6M in Breach of AI Imaging Contract with ChemImage

Recently, the Federal Court of New York made a significant ruling: Ethicon, a subsidiary of Johnson & Johnson, was ordered to pay $76.6 million (approximately550 MillionRMB) compensation.

Reportedly, this commercial dispute began in 2019 when ChemImage and Ethicon signed a contract to jointly develop AI-based optical imaging technology for surgical procedures. However, in March 2023, Ethicon terminated the contract citing "failure to achieve key milestones" and refused to pay the termination fee; ChemImage accused Ethicon of deliberately creating obstacles through technical blockades. Recently, a judge in the Southern District of New York officially announced the ruling that Johnson & Johnson's Ethicon must pay $76,559,521 for breaching its contract with ChemImage.

In fact, as early as May this year, the court had already determined that Ethicon breached the contract. This ruling is the final characterization and liability determination of the case. This huge compensation figure has attracted much attention in the medical device industry.

It is reported that ChemImage, a startup biotechnology company, has been committed to exploring the application of optical imaging and analysis technology in the medical field since its establishment.

In 2019, ChemImage signed a collaboration agreement with Ethicon, under which the two parties will develop AI-based optical imaging technology for surgical procedures. According to the terms, ChemImage initially received a $7 million upfront payment. Subsequently, ChemImage is required to achieve a series of research and development as well as regulatory milestones, each associated with substantial potential payments, totaling up to $1.5 billion. This collaboration model aims to incentivize ChemImage to fully commit to technological development while laying the groundwork for Ethicon’s future presence in the surgical market.

However, by 2023, the project encountered obstacles, causing significant delays behind the expected schedule. In March 2023, Ethicon announced the "justified" termination of the agreement, citing ChemImage's failure to achieve a critical milestone. However, ChemImage firmly believed this to be a unilateral breach of contract by Ethicon and promptly filed a lawsuit against Johnson & Johnson, accusing it of maliciously interfering with the contract and sabotaging the cooperative relationship between the two parties.

During the court proceedings, a detailed review of the cooperation specifics and project progress was conducted, concluding that ChemImage did have some instances of non-compliance during the collaboration. However, Ethicon also acted improperly in handling the partnership issues.

Ultimately, the court ruled that ChemImage is entitled to multiple compensations, including damages related to intellectual property loss. However, considering the fact that the collaboration failed, the court made a discounted adjustment to the compensation amount. Regarding the discount rate, Ethicon proposed 40%, while ChemImage deemed 17% more reasonable.

The court ultimately adopted ChemImage's claims and, after considering various factors, determined the final compensation amount: ChemImage was awarded a $40 million termination fee, along with slightly over $37 million in damages and compensation for intellectual property loss. However, $510,000 received by ChemImage from asset sales, as agreed upon by both parties, was deducted. In summary, the court ruled that Ethicon, a subsidiary of Johnson & Johnson, must pay a total of $76,559,521.

Public information shows that Ethicon, as an important subsidiary of Johnson & Johnson in the medical device field, has long occupied a leading position in the global surgical instrument market. Its product line is rich and diverse, covering several core areas such as sutures, staplers, and cutting instruments.

However, in recent years, Ethicon has faced numerous challenges and difficulties.

Product Recall Situation: On May 19, 2025, Ethicon Endo-Surgery, LLC, announced a voluntary recall of certain products due to an increase in complaints regarding firing issues with specific batches of staple cartridges (Model VASECR35) when used with the electric laparoscopic linear vascular stapler during surgical procedures. The recall was classified as Class I.

Moreover, on October 18, 2024, Ethicon LLC initiated a Class II recall of synthetic absorbable surgical sutures due to material mix-ups that resulted in some packages containing incorrect needle types and suture specifications. Frequent product recalls not only damage the company's brand image but also increase operational costs and potential legal risks for the business.

In terms of legal litigation, Ethicon has also been plagued by troubles. In April 2022, according to a ruling issued by the Fourth District Court of California, Ethicon faced a $302 million fine for deceptively marketing female pelvic mesh implants. Although Johnson & Johnson stated it would continue to appeal, the incident had already negatively impacted the company's reputation. The recent verdict ordering a massive compensation payment to ChemImage further exacerbated Ethicon’s financial situation and market credibility.

Some analyses suggest that, in the face of market competition, as the pace of technological innovation in the medical device industry accelerates, an increasing number of emerging companies are gaining prominence through innovative technologies. Companies like ChemImage, which focus on cutting-edge technology development, are exerting considerable competitive pressure on traditional medical device giants such as Ethicon. At the same time, with the growing stringency of global medical device market regulations, Ethicon needs to allocate more resources to meet regulatory requirements and ensure product quality and safety, which has, to a certain extent, squeezed the company's profit margins.

Currently, as the medical device industry moves towards intelligence and precision, the surgical robot field has become a high ground fiercely contested by major giants. With its deep brand heritage and extensive business layout, Johnson & Johnson has carried out a series of strategic layouts in the surgical robot track.

As early as 2015, Ethicon under Johnson & Johnson collaborated with Google, later co-founding Verb Surgical to embark on the development of surgical robots. Although the outcomes fell short of expectations, they accumulated valuable technology and experience.

In 2019, Johnson & Johnson acquired Auris for $3.4 billion, obtaining its core product, the Monarch surgical robot, which can perform lung cancer diagnosis and treatment through natural orifices, strengthening Johnson & Johnson's core technology and product line in this field. This acquisition also became a key turning point in Johnson & Johnson's strategic layout in surgical robotics.

After completing the acquisition of Auris, Johnson & Johnson did not halt its progress in the development of surgical robots. It has continued to invest substantial resources into technology research and product iteration. In November 2023, Johnson & Johnson’s medical technology division announced plans to submit an application to the U.S. FDA in the second half of 2024 to initiate clinical trials for its surgical robot system, Ottava.

In April 2025, Johnson & Johnson Medical Technologies announced that its Ottava surgical robot platform had successfully completed the first batch of clinical cases, marking a critical step forward for this innovative technology in the field of minimally invasive surgery.

It is reported that Ottava is a multi-specialty soft tissue surgical robot that supports multi-quadrant operational needs for complex surgeries. Its core innovations include:

• Six-Arm Collaborative Design: By integrating six robotic arms, Ottava can adapt to patient anatomy and surgical specialty requirements, covering upper abdominal general surgeries such as gastric bypass, sleeve gastrectomy, small bowel resection, and hiatal hernia repair.

  
  

• Integrated Operating Table: Four robotic arms are embedded in a standard-sized operating table, achieving an "invisible design." They unfold when needed and retract under the table when not in use, optimizing the utilization of operating room space.

  
  

• Clinical Workflow Adaptation: The system allows surgical teams to adjust operational procedures according to actual needs, improving surgical efficiency and safety.

  
  

Notably, in the Chinese market, Johnson & Johnson is advancing its layout across multiple dimensions. Monarch has become the first robot-assisted platform for natural-orifice diagnosis and treatment approved in China; the new Ethicon factory in Suzhou lays the foundation for localized production of related consumables; and the AI surgical planning system co-developed with local companies has served more than 20,000 patients.

It should be noted that, in the face of fierce industry competition, Johnson & Johnson still faces significant challenges. In the market, Intuitive Surgical's da Vinci robot holds a dominant position, while domestic and international companies such as MicroPort are also on the rise; technologically, there is a need to overcome issues like operational precision and remote surgery; stricter regulations have also increased the difficulty of product launches.

So, how will Johnson & Johnson layout in the surgical robot field in the future? After the commercial dispute with ChemImage is resolved, will Johnson & Johnson adjust its layout in related fields? We will continue to follow up.